Mersana Therapeutics logo

Mersana TherapeuticsNASDAQ: MRSN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 June 2017

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$265.60 M
-76%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector
253.19
-17%vs. 3y high
100%vs. sector
-99%vs. 3y high
72%vs. sector

Price

after hours | Tue, 19 Nov 2024 21:28:50 GMT
$2.15+$0.06(+2.87%)

Dividend

No data over the past 3 years
$12.60 M$7.64 M
$12.60 M-$11.50 M

Analysts recommendations

Institutional Ownership

MRSN Latest News

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO & COO Conference Call Participants Tara Bancroft - TD Cowen Yen-Der Li - Leerink Partners Charles Zhu - LifeSci Capital Ashiq Mubarack - Citi Yige Guo - Guggenheim Justin Zelin - BTIG Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
zacks.com13 November 2024 Sentiment: POSITIVE

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.35 per share a year ago.

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
globenewswire.com06 November 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com13 August 2024 Sentiment: NEGATIVE

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago.

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
globenewswire.com06 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com22 May 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
Seeking Alpha28 February 2024 Sentiment: POSITIVE

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research28 February 2024 Sentiment: NEUTRAL

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.44 per share a year ago.

Mersana Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire27 February 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

  • 1(current)

What type of business is Mersana Therapeutics?

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

What sector is Mersana Therapeutics in?

Mersana Therapeutics is in the Healthcare sector

What industry is Mersana Therapeutics in?

Mersana Therapeutics is in the Biotechnology industry

What country is Mersana Therapeutics from?

Mersana Therapeutics is headquartered in United States

When did Mersana Therapeutics go public?

Mersana Therapeutics initial public offering (IPO) was on 28 June 2017

What is Mersana Therapeutics website?

https://www.mersana.com

Is Mersana Therapeutics in the S&P 500?

No, Mersana Therapeutics is not included in the S&P 500 index

Is Mersana Therapeutics in the NASDAQ 100?

No, Mersana Therapeutics is not included in the NASDAQ 100 index

Is Mersana Therapeutics in the Dow Jones?

No, Mersana Therapeutics is not included in the Dow Jones index

When was Mersana Therapeutics the previous earnings report?

No data

When does Mersana Therapeutics earnings report?

The next expected earnings date for Mersana Therapeutics is 28 February 2025